Health Canada has approved a self-injectable subcutaneous (under-the-skin) form of Entyvio (vedolizumab) as an at-home maintenance therapy for adults with Crohn’s disease (CD). The approval follows an earlier decision to authorize the medication for ulcerative colitis. These two conditions comprise the main forms of inflammatory bowel disease (IBD), of which Canada has the world’s highest prevalence. “Having a formulation of vedolizumab that can be self-administered is an important new delivery method for IBD patients with…

You must be logged in to read/download the full post.